TG Therapeutics Inc
Research TG Therapeutics Inc (TGTX) on Bullrun: market cap USD 8.48B, P/E 20.2. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerTGTX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 8.48B
- P/E20.2
- Financial periodQ2 2026
- RevenueUSD 240.34M
- Net incomeUSD 7.78M
- Free cash flowUSD 38.97M
- Gross margin82.9%
Valuation Snapshot
latest market cap is USD 8.48B; P/E is 20.2.
Peer valuation comparison
Latest P/E is 20.18x versus a Healthcare sector median of 24.46x (17.5% below).
Latest P/E is 20.18x versus a United States median of 24.87x (18.8% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 616.29M | USD 447.20M | -USD 24.99M | 83.7% | 2.77 | USD 79.15M | USD 245.65M | USD 648.02M |
| FY2024 | USD 329.00M | USD 23.40M | -USD 40.56M | 88.3% | 0.15 | USD 179.89M | USD 244.43M | USD 222.36M |
| FY2023 | USD 233.66M | USD 12.70M | -USD 31.41M | 94.0% | 0.09 | USD 92.93M | USD 100.12M | USD 160.50M |
| FY2022 | USD 2.79M | -USD 198.30M | -USD 176.18M | 90.5% | -1.65 | USD 102.30M | USD 71.14M | USD 58.59M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 8.48B | 20.2 | n/a | n/a |
| 2025 | 2025-12-31 | USD 4.63B | 10.7 | n/a | n/a |
| 2024 | 2024-12-31 | USD 4.69B | 215.0 | n/a | n/a |
| 2023 | 2023-12-29 | USD 2.59B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 1.72B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 2.72B | n/a | n/a | n/a |
About TG Therapeutics Inc
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is TG Therapeutics Inc's market cap?
TG Therapeutics Inc's market capitalization is USD 8.48B.
What is TG Therapeutics Inc's P/E ratio?
TG Therapeutics Inc's price-to-earnings (P/E) ratio is 20.2.
What does TG Therapeutics Inc do?
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.